Clinical Trials Browser

Phase 3 × Carcinoma, Renal Cell × Sunitinib × Clear all

NCT02811861 2026-02-23

CLEAR

Phase 3 Active not recruiting

1,069 enrolled 12 charts 1 FDA

Carcinoma, Renal Cell

NCT02853331 2026-02-02

KEYNOTE-426

Phase 3 Completed

861 enrolled 24 charts 1 FDA

Carcinoma, Renal Cell

NCT03091192 2026-01-23

Savolitinib vs. Sunitinib in MET-driven PRCC.

Phase 3 Active not recruiting

60 enrolled 15 charts

Carcinoma, Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Neoplasms by Site, Urologic Neoplasms

NCT06726421 2026-01-15

STROKER

Phase 3 Recruiting

Carcinoma, Renal Cell, Kidney Neoplasms

NCT07165418 2025-09-10

A Comparison of Vorolanib Tablets Combined With Everolimus Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma Who Have Progressed After Treatment With Immunotherapy Monotherapy or in Combination With TKI

Phase 3 Not yet recruiting

Carcinoma, Renal Cell

NCT00930033 2025-09-05

CARMENA

Phase 3 Completed

Carcinoma, Renal Cell

NCT02684006 2025-07-30

JAVELIN Renal 101

Phase 3 Completed

886 enrolled 37 charts 1 FDA

Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Neoplasms

NCT03260894 2025-07-29

Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)

Phase 3 Completed

129 enrolled 13 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT02231749 2025-06-26

Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)

Phase 3 Completed

1,390 enrolled 18 charts 1 FDA

Carcinoma, Renal Cell

NCT03141177 2025-06-06

CheckMate 9ER

Phase 3 Active not recruiting

701 enrolled 17 charts 1 FDA

Carcinoma, Renal Cell

NCT05043090 2025-05-08

SAMETA

Phase 3 Active not recruiting

Carcinoma, Carcinoma, Renal Cell, Neoplasm Metastasis

NCT00720941 2025-03-30

COMPARZ

Phase 3 Completed

1,110 enrolled 27 charts

Carcinoma, Renal Cell

NCT03729245 2023-04-11

A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)

Phase 3 Terminated

623 enrolled 14 charts

Carcinoma, Renal Cell, Kidney Neoplasms

NCT02420821 2023-01-30

IMmotion151

Phase 3 Completed

915 enrolled 40 charts

Carcinoma, Renal Cell

NCT01265901 2017-10-12

IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma

Phase 3 Completed

Carcinoma, Renal Cell

NCT01064310 2017-04-17

PISCES

Phase 3 Completed

169 enrolled 16 charts

Carcinoma, Renal Cell, Neoplasms, Patient Preference

NCT00083889 2010-01-26

SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma

Phase 3 Completed

750 enrolled 20 charts

Carcinoma, Renal Cell